Cargando…
Camptothecin Sensitizes Hepatocellular Carcinoma Cells to Sorafenib- Induced Ferroptosis Via Suppression of Nrf2
Sorafenib is a potent inducer of ferroptosis used to manage hepatocellular carcinoma (HCC). The ferroptosis induced by sorafenib activates the p62–Keap1–Nrf2 pathway. Abnormal activation of Nrf2 reduces sorafenib’s efficiency and ferroptosis action and induces sorafenib’s resistance. Consequently, o...
Autores principales: | Elkateb, Ahmed S., Nofal, Shahira, Ali, Sahar A., Atya, Hanaa B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359394/ https://www.ncbi.nlm.nih.gov/pubmed/37171695 http://dx.doi.org/10.1007/s10753-023-01823-4 |
Ejemplares similares
-
Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma
por: Sun, Liwei, et al.
Publicado: (2023) -
GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis
por: Wang, Qiujie, et al.
Publicado: (2021) -
Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs
por: Chen, Feng, et al.
Publicado: (2017) -
Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis
por: Li, Yan, et al.
Publicado: (2023) -
Correction: Camptothecin suppresses NRF2–ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs
por: Chen, Feng, et al.
Publicado: (2019)